Braidwell »

Karyopharm Therapeutics Inc note 3.000%10/1 shares owned by Braidwell

Quarter-by-quarter ownership of Karyopharm Therapeutics Inc note 3.000%10/1 shares owned by Braidwell from 13F filings

Historical chart of Braidwell investment in Karyopharm Therapeutics Inc note 3.000%10/1

Tip: Access up to 7 years of quarterly data

All positions including Karyopharm Therapeutics Inc note 3.000%10/1 held by Braidwell consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Karyopharm Therapeutics Inc note 3.000%10/1 by Braidwell

Quarter filed Position value Share count Share price at filing
2023-12-31 $33M 66M 0.50
2023-09-30 $41M 66M 0.62
2023-06-30 $43M 66M 0.65
2023-03-31 $51M 66M 0.78
2022-12-31 $49M 66M 0.75

More positions owned by Braidwell

Guardant Health Note 11/1 (Principal)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Ascendis Pharma A/s Note 2.250% 4/0 (Principal)
Exact Sciences Corp Note 0.375% 3/0 (Principal)
Novocure Note 11/0 (Principal)
Neurocrine Biosciences (NBIX)
Vaxcyte (PCVX)
Xenon Pharmaceuticals (XENE)
Nuvasive Note 0.375% 3/1 (Principal)
Insulet Corp Note 0.375% 9/0 (Principal)
Tandem Diabetes Care Note 1.500% 5/0 (Principal)
Day One Biopharmaceuticals I (DAWN)
Irhythm Technologies (IRTC)
Argenx Se Sponsored Adr (ARGX)
Bridgebio Pharma Note 2.250% 2/0 (Principal)

View all positions for Braidwell

Top funds holding Karyopharm Therapeutics Inc note 3.000%10/1

Braidwell
Highbridge Capital Management
Davidson Kempner Capital Management
Context Capital Management
Birch Grove Capital
Capstone Investment Advisors
Lazard Asset Management
DeepCurrents Investment Group
BLB^B Advisors
Jpmorgan Chase & Co

View all funds holding Karyopharm Therapeutics Inc note 3.000%10/1